Covington & Burling advised Humacyte, while Paul Hastings advised the underwriters in the offering. Humacyte, Inc. (Nasdaq: HUMA) announced its offering of 25,000,000 shares of common...
You must be a Standard 1 Year member to access this content.
Thompson Hine advised Vaxart, while Paul Hastings LLP advised Oppenheimer & Co. as the sole bookrunner in the offering. Vaxart, Inc. (Nasdaq: VXRT) announced an underwritten...
You must be a Standard 1 Year member to access this content.
Davis Polk & Wardwell advised ProKidney, while Paul Hastings advised Jefferies, J.P. Morgan, and Guggenheim Securities, as joint book-running managers, in the transaction. ProKidney Corp. (Nasdaq:...
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised Monte Rosa Therapeutics, while Paul Hastings advised TD Cowen and Wedbush PacGrow, as joint book-running managers, in the offering. Monte Rosa Therapeutics, Inc....
You must be a Standard 1 Year member to access this content.
Cooley advised INOVIO Pharmaceuticals, while Paul Hastings LLP advised Oppenheimer & Co. and Citizens JMP as joint book running managers in the offering. INOVIO executed an...
You must be a Standard 1 Year member to access this content.
Paul Hastings LLP advised Piper Sandler and Co. as lead placement agent, and Oppenheimer & Co. as placement agent in the transaction. Skye Bioscience, Inc. (OTCQB:...
You must be a Standard 1 Year member to access this content.
Paul Hastings LLP advised J.P. Morgan and Leerink Partners as co-lead placement agents, and Stifel co-placement agent, in the transaction. Lexeo Therapeutics, Inc. (Nasdaq: LXEO) has entered...
You must be a Standard 1 Year member to access this content.
Covington & Burling represented Humacyte, while Paul Hastings advised TD Cowen, Cantor and BTIG in the offering. Humacyte, Inc. executed an underwritten public offering of 13,400,000 shares...
You must be a Standard 1 Year member to access this content.
Paul Hastings LLP advised Leerink Partners on the matter. PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the...
You must be a Standard 1 Year member to access this content.
Paul Hastings LLP advised the underwriters. American Homes 4 Rent (NYSE: AMH) announced that its operating partnership, American Homes 4 Rent, L.P. (the “Operating Partnership”), has...
You must be a Standard 1 Year member to access this content.
Paul Hastings LLP advised the lead placement agent and the placement agent. Skye Bioscience, Inc. (OTCQB: SKYE), a clinical stage biotechnology company focused on the discovery,...
You must be a Standard 1 Year member to access this content.
Paul Hastings LLP advised Jefferies LLC as sole book running manager in connection with Esperion Therapeutics, Inc.’s offering. Esperion Therapeutics, Inc. announced the pricing of its...
You must be a Standard 1 Year member to access this content.
